Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials

Publication | Closed Access

DOI

322

Citations

References

2006

Year

Charles B. Hicks, Pedro Cahn, David A. Cooper, Sharon Walmsley, Christine Katlama, Bonaventura Clotet, Adriano Lazzarin, Margaret Johnson, Dietmar Neubacher, Douglas L. Mayers,

The Lancet

Durable EfficacyTreatment-experienced Hiv-1-infected PatientsHiv/aids CounsellingStrategic InterventionHealth SciencesMedicineTreatment And PreventionAntiviral Drug DevelopmentClinical TrialsResistance Mutation (Virology)Antiviral TherapyPharmacotherapyAntiviral DrugHivPharmacologyDrug Resistance